ENVALITH
浜松ホトニクス株式会社 logo

HAMAMATSU PHOTONICS K.K.

6965・Prime Market・Electric Appliances

浜松ホトニクス株式会社 logo
HAMAMATSU PHOTONICS K.K.6965

Electron Tube Business

Hamamatsu Photonics' core segment manufacturing and selling Photomultiplier Tubes, Imaging Devices, and light sources

PeriodCurrentPreviousChange
Net sales (H1 FY2026, ending March 2026)¥38,417 million¥37,245 million (H1 FY2025, ending March 2025)↑
Operating income (H1 FY2026, ending March 2026)¥10,873 million¥10,005 million (H1 FY2025, ending March 2025)↑
Operating margin (H1 FY2026, ending March 2026)28.3%26.9% (H1 FY2025, ending March 2025)↑
Net sales (FY2025, ending March 2025, full year)¥71,906 million——
Operating income (FY2025, ending March 2025, full year)¥18,953 million——
Operating margin (FY2025, ending March 2025, full year)26.4%——

Business Details

A business segment that manufactures and sells Photomultiplier Tubes, Imaging Devices, and light sources. Sold globally through overseas subsidiaries such as Hamamatsu Corporation (U.S.) and Hamamatsu Photonics Deutschland (Germany). The segment has a broad presence across the medical/bio, industrial, and analytical fields, with Photomultiplier Tubes and Xenon Lamps for generative AI-related semiconductor manufacturing and inspection equipment, and Microfocus X-ray Sources for data server board inspection as core offerings. In the first half of FY2026 (ending March 2026), net sales were ¥38,417 million, accounting for approximately 34% of total group sales, making it the mainstay business.

Recent Overview

Driven by expanding generative AI and semiconductor demand, both H1 net sales and operating income increased year on year

In the first half of FY2026 (ending March 2026) (October 2025 to March 2026), the Electron Tube Business recorded net sales of ¥38,417 million (up 3.1% year on year) and operating income of ¥10,873 million (up 8.7% year on year). Sales of Photomultiplier Tubes and Xenon Lamps for semiconductor manufacturing and inspection equipment increased due to expanding semiconductor demand centered on generative AI. Microfocus X-ray Sources also increased due to rising demand for data server board inspection. Meanwhile, Deuterium Lamps for analytical instruments such as liquid chromatographs decreased. The operating margin improved to 28.3% from 26.9% in the same period of the previous year, maintaining the highest level of profitability within the group.

Key Products

product
Photomultiplier Tube

Deployed broadly across the medical/bio, analytical, and industrial fields. In the first half under review, sales for semiconductor manufacturing and inspection equipment increased, driven by expanding semiconductor demand centered on generative AI.

product
Microfocus X-ray Source

Sales increased in the first half under review due to rising demand for data server board inspection. Expanding data center investment driven by the spread of generative AI is driving demand.

product
Xenon Lamp

Sales for semiconductor manufacturing and inspection equipment increased in the first half under review, driven by expanding semiconductor demand centered on generative AI.

product
Deuterium Lamp

Deployed for analytical instruments such as liquid chromatographs. Sales decreased in the first half under review. Rising demand driven by tightening regulations in the analytical field is a medium- to long-term growth driver.

product
Imaging Devices

An imaging product group deployed for the medical/bio and industrial fields. A key product category in the Electron Tube Business alongside Photomultiplier Tubes.

Growth Drivers

  • Increased demand for data server board inspection due to the spread of generative AI (Microfocus X-ray Source)
  • Expanding demand for Photomultiplier Tubes and Xenon Lamps for semiconductor manufacturing and inspection equipment, centered on generative AI
  • Multi-regional expansion through a global sales network (overseas subsidiaries in the U.S., Europe, and Asia)
  • Rising demand for analytical technology driven by tightening regulations in the analytical field (Deuterium Lamps, etc.)
  • Innovative advancement of device technology and expansion into high-value-added module and system products

Risks

  • Decreased demand in the medical/bio field due to budget cuts at public research institutions such as the U.S. National Institutes of Health (NIH)
  • Sluggish demand for Deuterium Lamps used in analytical instruments such as liquid chromatographs
  • Unstable demand for lithium-ion battery non-destructive inspection equipment due to stagnation and volatility in the EV market
  • Intensifying price competition in the Chinese market and heightened geopolitical risk
  • Foreign exchange risk (U.S. dollar, euro, and Chinese yuan affecting operating income)
  • Risk of capital expenditure restraint spreading due to inventory adjustment phases in the semiconductor industry

Optical Semiconductor Business

Hamamatsu Photonics' largest segment, capturing generative AI and FA demand

PeriodCurrentPreviousChange
Net sales (H1 FY2026, ending March 2026)¥42,969 million¥39,234 million (H1 FY2025, ending March 2025)↑
Operating income (H1 FY2026, ending March 2026)¥7,827 million¥6,709 million (H1 FY2025, ending March 2025)↑
Operating margin (H1 FY2026, ending March 2026)18.2%17.1% (H1 FY2025, ending March 2025)↑
Net sales, year-on-year change (H1 FY2026, ending March 2026)+9.5%—↑
Operating income, year-on-year change (H1 FY2026, ending March 2026)+16.7%—↑
Net sales (FY2025, ending March 2025, full year)¥79,505 million——
Operating income (FY2025, ending March 2025, full year)¥12,583 million——

Business Details

Optical semiconductor devices (Silicon Photodiodes, Flat Panel Sensors, Image Sensors, etc.) are manufactured and sold by the Company and its overseas subsidiaries. The segment covers a wide range of applications, including the medical/bio field (X-ray CT, dental diagnostic equipment), the industrial field (semiconductor manufacturing and inspection equipment, FA robot control), and high-energy physics experiments. In the first half of FY2026 (ending March 2026), net sales were ¥42,969 million, accounting for approximately 38.2% of total company sales, making it the largest segment within the group.

Recent Overview

Driven by generative AI and FA demand, both net sales and operating income achieved double-digit growth

In the first half of FY2026 (ending March 2026) (October 2025 to March 2026), the Optical Semiconductor Business achieved higher sales and profit, with net sales of ¥42,969 million (up 9.5% year on year) and operating income of ¥7,827 million (up 16.7% year on year). Image Sensors for semiconductor manufacturing and inspection equipment increased due to expanding semiconductor demand centered on generative AI, and Photodiodes for the FA field also grew. Meanwhile, academic research-related sales decreased due to the completion of Photodiode Array deliveries for a European high-energy physics experiment project. The operating margin improved to 18.2% from 17.1% in the same period of the previous year.

Key Products

product
Image Sensor

Demand for semiconductor manufacturing and inspection equipment increased against the backdrop of expanding semiconductor demand centered on generative AI. Sales growth continued in the first half under review as well.

product
Silicon Photodiode

Demand expanded in the factory automation (FA) field, including control of industrial robots. Sales growth was confirmed in the first half under review.

product
Flat Panel Sensor

A high-value-added product supplied for the medical/bio field (X-ray CT, dental diagnostic equipment, etc.).

product
Photodiode Array

Deliveries were completed in the first half under review for a European high-energy physics experiment project, causing academic research-related sales to turn to a decline.

Growth Drivers

  • Increased Image Sensor sales for semiconductor manufacturing and inspection equipment due to expanding demand for high-performance semiconductors for generative AI and data centers
  • Expanding demand for Photodiodes for industrial robot control in the factory automation (FA) field
  • Group synergies and accelerated growth in new markets through the consolidation of Fairchild Imaging, Inc. as a subsidiary
  • Business expansion into high-value-added module and system products that highly integrate light-receiving and light-emitting technologies

Risks

  • Profit pressure on Silicon Photodiodes for X-ray CT and other products due to intensifying price competition in the Chinese market
  • Risk of capital expenditure restraint in the medical/bio field due to high interest rates and economic conditions in the U.S. and Europe
  • Risk of fluctuation in Image Sensor demand due to inventory adjustment phases and capital expenditure cycle changes in the semiconductor industry
  • Risk of a temporary decline in academic research-related demand following the completion of deliveries for the European high-energy physics experiment project
  • Risk of supply chain disruption due to geopolitical risk (U.S. trade policy and reciprocal tariff measures)

Imaging & Measurement Systems Business

A highly profitable segment offering imaging processing and measurement equipment for medical, bio, and industrial applications

PeriodCurrentPreviousChange
Net sales (H1 FY2026, ending March 2026)¥17,342 million¥16,038 million (H1 FY2025, ending March 2025)↑
Operating income (H1 FY2026, ending March 2026)¥5,219 million¥4,832 million (H1 FY2025, ending March 2025)↑
Operating margin (H1 FY2026, ending March 2026)30.1%30.1% (H1 FY2025, ending March 2025)—
Net sales (FY2025, ending March 2025, full year)¥32,703 million——
Operating income (FY2025, ending March 2025, full year)¥9,698 million——
Operating margin (FY2025, ending March 2025, full year)29.7%——

Business Details

A segment that manufactures and sells imaging processing and measurement equipment. Core products are the Pathology Digital Slide Scanner and the Digital Camera (for Scientific Measurement). Against a backdrop of steady demand growth in Europe and the U.S., sales of scanners for remote pathology diagnosis grew, and demand for digital cameras for the life sciences and bio fields also recovered. The business is deployed globally through domestic and overseas sales subsidiaries.

Recent Overview

H1 net sales increased 8.1% year on year, driven by pathology diagnosis demand in Europe and the U.S. and recovery in bio-related cameras

In the first half of FY2026 (ending March 2026) (October 2025 to March 2026), net sales were ¥17,342 million (up 8.1% year on year) and operating income was ¥5,219 million (up 8.0% year on year). Against a backdrop of steady demand growth in Europe and the U.S., sales of Pathology Digital Slide Scanners increased, and demand for digital cameras for the life sciences and bio fields recovered, contributing to sales growth. The operating margin was maintained at approximately 30%, roughly in line with the same period of the previous year, and the segment's high-profitability profile continued.

Key Products

product
Pathology Digital Slide Scanner

Demand for remote pathology diagnosis is expanding, mainly in Europe and the U.S., and sales growth continued in the first half under review as well. Expansion of sales channels and coverage regions is supporting growth.

product
Digital Camera (for Scientific Measurement)

Demand in the life sciences and bio fields recovered in the first half under review, contributing to sales growth. The previous period had been sluggish due to factors such as public budget cuts, but it has turned to a recovery trend.

product
Semiconductor Failure Analysis System

Demand is expanding against the backdrop of increasing investment in high-performance semiconductors for generative AI. It is competitive in the semiconductor manufacturing and inspection equipment market due to its high operability and functionality.

Growth Drivers

  • Increased sales of Pathology Digital Slide Scanners due to expanding demand for remote pathology diagnosis (telepathology), mainly in Europe and the U.S.
  • Recovery in demand for digital cameras for the life sciences and bio fields
  • Increased demand for Semiconductor Failure Analysis Systems due to expanding investment in high-performance semiconductors for generative AI
  • Expansion of coverage regions for Pathology Digital Slide Scanners through expanded sales channels
  • Product competitiveness through high operability and functionality in the semiconductor manufacturing and inspection equipment market

Risks

  • Risk of decreased demand for digital cameras and other products due to public budget cuts in the bio/research field (e.g., U.S. NIH budget cuts)
  • Risk of fluctuation in demand for failure analysis systems due to changes in the semiconductor investment cycle
  • Pressure on profit margins due to increased depreciation expenses accompanying increased capital expenditure
  • Possibility of supply chain disruption and cost increases due to heightened geopolitical risk
  • High dependence on the European and U.S. markets, with exposure to sales and profit impact from foreign exchange fluctuations (particularly yen appreciation)

Laser Business

A segment in a growth investment phase manufacturing and selling laser equipment and components

PeriodCurrentPreviousChange
Net sales (H1 FY2026, ending March 2026)¥10,480 million¥11,295 million (H1 FY2025, ending March 2025)↓
Operating loss (H1 FY2026, ending March 2026)-¥3,475 million-¥1,371 million (H1 FY2025, ending March 2025)↓
Net sales (current fiscal year, full year)¥22,255 million——
Operating loss (current fiscal year, full year)-¥4,365 million——

Business Details

The Company and NKT Photonics A/S (Denmark), acquired in May 2024, manufacture and sell laser equipment and Laser Equipment Components, deployed through domestic and overseas sales subsidiaries. Core products are the Stealth Dicing Engine, which cuts silicon wafers at high speed and high quality, and Fiber Lasers. While benefiting from generative AI-related semiconductor manufacturing capital expenditure, the segment continues to record operating losses due to a heavy goodwill amortization burden associated with the acquisition.

Recent Overview

H1 net sales decreased 7.2% year on year, and the operating loss widened significantly compared to the same period of the previous year

In the first half of FY2026 (ending March 2026) (October 2025 to March 2026), the Laser Business recorded net sales of ¥10,480 million (down 7.2% year on year) and an operating loss of ¥3,475 million (compared to an operating loss of ¥1,371 million in the same period of the previous year). Sales of Stealth Dicing Engines remained steady due to strong capital expenditure related to generative AI, but sales of lasers for laser microscopes decreased, resulting in an overall decline in sales and a widening loss.

Key Products

product
Stealth Dicing Engine

Demand has remained steady against the backdrop of expanding capital expenditure on semiconductor manufacturing for generative AI. Sales are reported to have remained steady in the first half of FY2026 (ending March 2026) as well.

product
Fiber Laser

Fiber lasers manufactured by the Danish company acquired in May 2024. Used for applications including laser microscopes, but sales of lasers for laser microscopes decreased in the first half of FY2026 (ending March 2026).

product
Laser Equipment Components

The Company aims to create synergies through expansion into high-value-added module and system products that integrate light-receiving and light-emitting functions.

Growth Drivers

  • Steady demand for Stealth Dicing Engines due to expanding investment in semiconductor manufacturing and inspection equipment for generative AI
  • Acquisition of fiber laser technology and expansion of sales scale through the acquisition of NKT Photonics A/S
  • Creation of synergies through expansion into high-value-added module and system products integrating light-receiving and light-emitting functions
  • Continued expansion of wafer processing demand accompanying the recovery of capital expenditure in the semiconductor industry

Risks

  • Continued heavy amortization burden from goodwill associated with the acquisition (balance of ¥30,064 million at the end of the previous fiscal year, ¥29,700 million at the end of the first half), leading to a widening operating loss
  • The operating loss for the first half of FY2026 (ending March 2026) expanded significantly to ¥3,475 million from ¥1,371 million in the same period of the previous year, revealing a delay in profitability
  • Decreased demand in some applications, such as fiber lasers for laser microscopes, is depressing net sales
  • Fluctuations in the semiconductor industry's capital expenditure cycle may partially restrain demand for Stealth Dicing Engines
  • Risk of supply chain disruption and cost increases due to U.S. trade policy, reciprocal tariff measures, and heightened geopolitical risk

Other Businesses

A non-optical-core business segment including the hotel business and a Chinese subsidiary's proprietary product business

PeriodCurrentPreviousChange
Net sales (H1 FY2026, ending March 2026)¥3,287 million¥2,931 million (H1 FY2025, ending March 2025)↑
Operating income (H1 FY2026, ending March 2026)-¥244 million (operating loss)¥858 million (H1 FY2025, ending March 2025)↓
Net sales (FY2025, ending March 2025, full year)¥5,679 million——
Operating income (FY2025, ending March 2025, full year)¥863 million——

Business Details

Other Businesses consists of two businesses: the hotel business operated by the subsidiary Iwata Grand Hotel Co., Ltd., and the proprietary product business of the subsidiary Beijing Hamamatsu Photon Techniques Inc. It is positioned as a business segment not included in Hamamatsu Photonics Group's four reportable segments (Electron Tube, Optical Semiconductor, Imaging & Measurement Systems, and Laser), and its share of total group sales is small at approximately 2.9% (H1 FY2026, ending March 2026). In the first half of FY2026 (ending March 2026), net sales increased 12.1% year on year, while the segment fell into an operating loss.

Recent Overview

H1 net sales increased 12.1% year on year, but the segment fell into an operating loss, a deterioration of ¥1,102 million year on year

In the first half of FY2026 (ending March 2026) (October 2025 to March 2026), net sales of Other Businesses were ¥3,287 million, up 12.1% year on year. Meanwhile, operating income deteriorated significantly, from an operating income of ¥858 million in the same period of the previous year to an operating loss of ¥244 million. This appears to be due to segment profitability being pressured by increased depreciation and lease expenses resulting from a significant increase in lease assets (a group-wide increase of ¥16,601 million in lease assets) associated with facility expansion following the completion of hotel rebuilding work.

Key Products

service
Hotel Business (Iwata Grand Hotel Co., Ltd.)

Hotel services such as lodging and banquets operated by the subsidiary Iwata Grand Hotel Co., Ltd. Facility renewal following the completion of hotel rebuilding work is expected to improve occupancy rates, but increased depreciation expenses accompanying the facility expansion are putting pressure on profitability.

product
Beijing Hamamatsu Photon Techniques Inc. Proprietary Products

A proprietary product business deployed for the Chinese market by the Chinese local subsidiary Beijing Hamamatsu Photon Techniques Inc. The company seeks to capture demand in the Chinese market, but geopolitical risk and intensifying price competition may affect the business environment.

Growth Drivers

  • Contribution to facility renewal and improved occupancy rates following the completion of hotel rebuilding work
  • Capturing demand in the Chinese market through Beijing Hamamatsu Photon Techniques Inc.'s proprietary products
  • Net sales continued on an increasing trend, up 12.1% year on year, maintaining top-line growth

Risks

  • Risk of increased depreciation and lease expenses following the completion of large-scale capital expenditure related to hotel rebuilding pressuring profit (an operating loss of ¥244 million was recorded in the first half of FY2026, ending March 2026)
  • Geopolitical risk and intensifying price competition in the Chinese market affecting the Chinese subsidiary's business
  • Risk that the relatively heavy fixed cost burden constrains profitability, given the segment's small scale of approximately 2.9% of total group sales
  • Risk of increased costs due to rising labor costs and inflation in the domestic hotel industry
  • Risk that a return to profitability in the second half remains uncertain, given the ¥1,102 million year-on-year deterioration in operating income/loss

Last updated: July 17, 2026